Authorized purpose: AI-Rad Companion Brain MR post-processes typical head-MR T1 MPRAGE images to automatically segment and quantify brain structures, compare normalized volumes with healthy reference data, and present numeric and visual reporting information to clinicians.
Clinical role
Post-processing, brain-structure segmentation, volumetric analysis, and report support.
Images and patients
MRI · Brain
Key limitation
Keep in mind: Results depend on the supported T1 sequence, acquisition quality, segmentation scope, and reference-population applicability. Outputs are adjunctive and require clinician review; they are not a standalone diagnosis.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: AI-Rad Companion Brain MR post-processes typical head-MR T1 MPRAGE images to automatically segment and quantify brain structures, compare normalized volumes with healthy reference data, and present numeric and visual reporting information to clinicians.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: Supported head-MR T1 MPRAGE studies.
Who uses it?Intended users: Radiologists, neurologists, neuroradiologists, and other trained clinicians reviewing brain MR.
What does the software produce?Output: Automatic segmentation and absolute or normalized volumes for labeled brain structures, with numeric and visual results archived for clinician review.
What is its most important limitation?Key limitation: Results depend on the supported T1 sequence, acquisition quality, segmentation scope, and reference-population applicability. Outputs are adjunctive and require clinician review; they are not a standalone diagnosis.
Clinical takeaway. Clinical role: AI-Rad Companion Brain MR post-processes typical head-MR T1 MPRAGE images to automatically segment and quantify brain structures, compare normalized volumes with healthy reference data, and present numeric and visual reporting information to clinicians.
Evidence takeaway. Evidence from the reviewed source record: The FDA package documents automatic segmentation and quantitative-analysis verification for the VA20 release; it does not establish independent patient-outcome benefit.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
AI-Rad Companion Brain MR post-processes typical head-MR T1 MPRAGE images to automatically segment and quantify brain structures, compare normalized volumes with healthy reference data, and present numeric and visual reporting information to clinicians.
Results depend on the supported T1 sequence, acquisition quality, segmentation scope, and reference-population applicability. Outputs are adjunctive and require clinician review; they are not a standalone diagnosis.
The FDA package documents automatic segmentation and quantitative-analysis verification for the VA20 release; it does not establish independent patient-outcome benefit.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The FDA package documents automatic segmentation and quantitative-analysis verification for the VA20 release; it does not establish independent patient-outcome benefit.
No single product-level sensitivity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No single product-level specificity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K193290 FDA evidence package for AI-Rad Companion Brain MR
DesignFDA 510(k) verification and validation evidence described in the exact submission
PopulationBrain
Scopeexact submission
Tested versionAI-Rad Companion Brain MR VA20
IndependenceSponsor or vendor study
K193290
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported head-MR T1 MPRAGE studies.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA package describes direct PACS archiving of results from T1 MPRAGE head MR; exact local DICOM routing, archive, and worklist behavior require acceptance testing.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes AI-Rad Companion Brain MR as updated with an architectural enhancement for its clinical extension to be deployed with the AI-Rad Companion Engine platform in a cloud-based environment. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "As an update to the previously cleared device, the following modifications have been made:" … "Architectural enhancement for the clinical extension to be deployed with the AI-Rad Companion Engine platform in a cloud-based environment". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Automatic segmentation and absolute or normalized volumes for labeled brain structures, with numeric and visual results archived for clinician review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Automatic segmentation and absolute or normalized volumes for labeled brain structures, with numeric and visual results archived for clinician review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes AI-Rad Companion Brain MR as updated with an architectural enhancement for its clinical extension to be deployed with the AI-Rad Companion Engine platform in a cloud-based environment. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "As an update to the previously cleared device, the following modifications have been made:" … "Architectural enhancement for the clinical extension to be deployed with the AI-Rad Companion Engine platform in a cloud-based environment". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA package describes direct PACS archiving of results from T1 MPRAGE head MR; exact local DICOM routing, archive, and worklist behavior require acceptance testing.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Only radiologists, neurologists, neuroradiologists, and other trained clinicians reviewing brain mr. should operate or interpret this product. Local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K193290 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Results depend on the supported T1 sequence, acquisition quality, segmentation scope, and reference-population applicability. Outputs are adjunctive and require clinician review; they are not a standalone diagnosis.
The FDA package describes direct PACS archiving of results from T1 MPRAGE head MR; exact local DICOM routing, archive, and worklist behavior require acceptance testing.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Results depend on the supported T1 sequence, acquisition quality, segmentation scope, and reference-population applicability. Outputs are adjunctive and require clinician review; they are not a standalone diagnosis.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price or product-specific reimbursement was established in the reviewed public material.
Monitor K193290 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Results depend on the supported T1 sequence, acquisition quality, segmentation scope, and reference-population applicability. Outputs are adjunctive and require clinician review; they are not a standalone diagnosis.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-04Last searched
25Fields reviewed
11Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Screened one PubMed title. It names only an automated brain-morphometry tool and does not identify AI-Rad Companion Brain MR VA20 or K193290, so it is quarantined. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared product version was established. Obtain a written quote separating license, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.